BETH ISRAEL DEACONESS MEDICAL CENTER

Aligos Therapeutics has begun dosing patients in the Phase 2 B-SUPREME study of ALG-000184, an investigational oral therapy for chronic hepatitis B virus infection.

Chromophobe renal cell carcinoma (ChRCC) demonstrates an immune-cold tumor microenvironment with significantly reduced CD8+ T-cell infiltration compared to clear cell RCC, explaining poor immunotherapy responses.

Iovance Biotherapeutics has appointed Marc R. Theoret, M.D., former FDA Deputy Center Director, to the newly created position of Senior Vice President, Regulatory Strategy.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

A major study analyzing over 265,000 sepsis patients found that statin treatment was associated with a 39% lower 28-day mortality rate compared to standard care alone.

The prevalence of depression among Americans aged 12 and older reached 13.1% during 2021-2023, marking a significant 60% increase from 8.2% in 2013-2014.

A comprehensive review of 301 clinical trials reveals only 10% of treatments for low back pain show evidence of effectiveness, with most providing only marginal relief compared to placebo.

Precision Neuroscience has received FDA 510(k) clearance for its Layer 7 Cortical Interface, marking the first full regulatory approval for a next-generation wireless brain-computer interface technology.

IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.

Shape Memory Medical has announced the first European enrollment in their AAA-SHAPE pivotal trial, evaluating the IMPEDE-FX RapidFill device for improving abdominal aortic aneurysm outcomes during endovascular repair.